Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. | Academic Article |
Why?
|
| Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm. | Academic Article |
Why?
|
| Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. | Academic Article |
Why?
|
| Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. | Academic Article |
Why?
|
| Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFa production. | Academic Article |
Why?
|
| Underdocumentation of Obesity by Medical Residents Highlights Challenges to Effective Obesity Care. | Academic Article |
Why?
|
| Obesity and obesity-related illnesses in borderline patients. | Academic Article |
Why?
|
| Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. | Academic Article |
Why?
|
| Risk of Knee Osteoarthritis With Obesity, Sarcopenic Obesity, and Sarcopenia. | Academic Article |
Why?
|
| The hunger-obesity paradox: obesity in the homeless. | Academic Article |
Why?
|
| Obesity,sarcopenic obesity or sarcopenia: Which is a greater risk for knee OA? | Academic Article |
Why?
|
| Use of Lisdexamfetamine to Treat Obesity in an Adolescent with Severe Obesity and Binge Eating. | Academic Article |
Why?
|
| The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: What Is New About Diet, Drugs, and Surgery for Obesity? | Academic Article |
Why?
|
| Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy. | Academic Article |
Why?
|
| ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management. | Academic Article |
Why?
|